JPMorgan Chase & Co. Buys 7,594 Shares of Sotera Health (NASDAQ:SHC)

JPMorgan Chase & Co. lifted its stake in Sotera Health (NASDAQ:SHC) by 3.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 255,341 shares of the company’s stock after buying an additional 7,594 shares during the quarter. JPMorgan Chase & Co. owned about 0.09% of Sotera Health worth $3,493,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Sotera Health by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 14,923,546 shares of the company’s stock worth $204,154,000 after acquiring an additional 173,341 shares during the period. Geode Capital Management LLC raised its position in shares of Sotera Health by 19.4% during the third quarter. Geode Capital Management LLC now owns 2,755,391 shares of the company’s stock valued at $46,026,000 after buying an additional 447,186 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Sotera Health by 45.1% in the fourth quarter. Bank of New York Mellon Corp now owns 1,630,736 shares of the company’s stock worth $22,308,000 after buying an additional 507,147 shares in the last quarter. Barclays PLC grew its stake in Sotera Health by 169.8% during the third quarter. Barclays PLC now owns 473,597 shares of the company’s stock valued at $7,909,000 after acquiring an additional 298,085 shares in the last quarter. Finally, Rhumbline Advisers increased its holdings in Sotera Health by 3.8% in the 4th quarter. Rhumbline Advisers now owns 399,171 shares of the company’s stock valued at $5,461,000 after acquiring an additional 14,616 shares during the last quarter. 91.03% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Barclays reduced their target price on Sotera Health from $16.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, April 10th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.20.

Sotera Health Stock Down 1.5 %

Shares of NASDAQ SHC opened at $10.32 on Tuesday. The stock has a market capitalization of $2.93 billion, a price-to-earnings ratio of 41.28 and a beta of 1.88. Sotera Health has a 12-month low of $9.53 and a 12-month high of $17.08. The company has a current ratio of 2.88, a quick ratio of 2.61 and a debt-to-equity ratio of 4.91. The firm’s 50-day moving average price is $11.76 and its 200-day moving average price is $13.26.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.